Enhanced Genomics extends Series A funding to $19 million

Thu, Sep 18, 2025

Cambridge, UK, 16 September 2025: Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has completed a financing round, extending its total Series A funding to $19 million. Investors in this latest funding are BGF, Parkwalk and Meltwind. 

Read the full article here.